Trial Profile
A Phase I Dose Escalation Study of Immunotherapy With IMMU-114 in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs IMMU 114 (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Gilead Sciences
- 16 Mar 2020 Status changed from completed to discontinued.
- 05 Apr 2019 Status changed from recruiting to completed.
- 17 Mar 2016 Results will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, as per Immunomedics media release